Iroko Pharmaceuticals
Iroko is a French AMF-regulated portfolio management company operating four SCPI and SCI real estate funds (Zen, Atlas, Next, Impact) across European markets, distributed through 1,000+ wealth management advisors and ten life insurance partners to retail and professional investors.
- Company typePrivate
- Founded2020
- HeadquartersPhiladelphia, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What Iroko Pharmaceuticals does
Iroko is a French independent portfolio management company (Société de Gestion de Portefeuille) authorized by the AMF (Autorisation GP-20000014, dated 8 June 2020) that manages four European real estate investment vehicles on behalf of individual and professional investors. Its product set comprises two SCPI funds (Iroko Zen, the diversified European SCPI with ISR label, and Iroko Atlas, the international opportunistic SCPI investing exclusively outside France) and two SCI vehicles (Iroko Next, combining yield and value-creation drivers with Finansol certification, and Iroko Impact, an SFDR Section 9 fund dedicated to the social and solidarity economy). Investment strategy is opportunistic and granular, with average asset size of €6M and assets spread across more than five European countries; the funds hold commercial, residential, hospitality, industrial and childcare real estate leased to tenants such as Tesco, Chronopost, Segula and LISI Aerospace.
The business model is fee-based, generating revenue through (1) recurring management commissions on rental income (e.g., 12% HT for Zen, 14.4–16.8% HT for Atlas), (2) acquisition commissions on new deals (3–4.8% HT), (3) development/work commissions up to 5% HT, and (4) capital gain commissions of 5% HT on Zen/Atlas and 20% HT on Next when gains exceed 5% of acquisition value. The €5,000 minimum investment and absence of subscription fees differentiate the offering from most French SCPI competitors. Distribution runs through three channels: a self-serve online subscription portal with scheduled payments from €50/month, a network of over 1,000 wealth management advisors (CGPs) supported by the Iroko Partners digital platform, and ten life insurance partners (Spirica, Generali, Prepar-Vie, OradeaVie, Selencia, APICIL, AG2R La Mondiale, Garance, UMR, CNP) offering the funds as unit-of-account investments.
The company was founded in 2020 by Gautier Delabrousse-Mayoux and is led by a 12-person team spanning partnerships, investments, fund management, compliance/ESG, investor relations and product/marketing, with a dedicated back-office validating 1,000+ subscription files per month at an average of 3 working days. Operations are headquartered in Paris (4 rue de la Pompe, 75016) with a Spanish subsidiary in Madrid (Arturo Soria 117, 28043 Madrid). Iroko Zen's 2024 distribution rate was 7.44% and Iroko Next delivered 6.21% versus a 5.68% target; Iroko Zen received a 15.55/20 ESG rating from the Les Echos Grand Prix SCPI 2024 and the firm collected multiple industry awards in 2024.
Iroko Pharmaceuticals firmographics
Firmographics- Name
- Iroko Pharmaceuticals
- Legal name
- Iroko
- Website
- https://iroko.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Iroko is a French AMF-regulated portfolio management company operating four SCPI and SCI real estate funds (Zen, Atlas, Next, Impact) across European markets, distributed through 1,000+ wealth management advisors and ten life insurance partners to retail and professional investors.
- Ownership category
- akta.pro rank
Iroko Pharmaceuticals industry classification
Industry- Product category
- Real Estate Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Open-End Investment Funds (525910)
- SIC
- Real Estate Agents & Managers (For Others) (6531), Real Estate Investment Trusts (6798)
- akta.pro primary industry
- Sustainable/Thematic Investing (Climate, Clean Tech, Water, Biodiversity) (FSAAALAB)
- akta.pro secondary industries
- ESG Integration / Responsible Investment Funds (Broad ESG) (FSANAJAL), ESG/Sustainable Investment Advisory (FSAEAAAJ)
Keywords
Where Iroko Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Iroko Pharmaceuticals business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Management Fees: Annual management commissions charged on rental income collected. For Iroko Zen: 12% excluding tax on rental income. For Iroko Atlas: 14.4% in Euro zone and 16.8% outside Euro zone on rental income. For Iroko Next: 0.9% max for directly held properties, 0.5% max for participations managed by third parties
- Acquisition Commissions: Commission charged when acquiring real estate assets. Iroko Zen: 3% excluding tax. Iroko Atlas: 4.8% excluding tax of purchase price
- Work/Development Commissions: Commission on renovation and development work. Up to 5% excluding VAT calculated on work amount, plus additional commissions for following and piloting work execution
- Capital Gain Commissions: Commission on capital gains from property sales. Only applies if capital gain exceeds 5% of acquisition value. 5% excluding tax of net selling price for Iroko Zen and Atlas. 20% excluding tax for Iroko Next
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Iroko Zen - SCPI with ISR Label |
| Subscription | Monthly | Iroko Atlas - International SCPI |
| Subscription | Monthly | Iroko Next - SCI with dual performance drivers |
| Subscription | Monthly | Iroko Impact - Social Economy SCI (SFDR Section 9) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Iroko Pharmaceuticals product offering
Product offeringCore offering
Iroko manages four European real estate investment funds — Iroko Zen SCPI, Iroko Atlas SCPI, Iroko Next SCI, and Iroko Impact SCI — distributed to investors through wealth-management advisors, French life-insurance wrappers (unit-of-account), and direct online subscription. The funds pursue opportunistic, granular, pan-European strategies with no entry fees and a focus on ESG certifications (ISR label, Finansol, SFDR 8/9).
Differentiator
Problem solved
Functional benefit
Brands
- Iroko Zen: SCPI (Société Civile de Placement Immobilier) - a patrimonial and resilient real estate fund with an opportunistic and European approach, targeting Western Europe including France and Germany.
- Iroko Atlas
- Iroko Next
- Iroko Impact
Products and services
- Iroko Zen (SCPI) SCPI (Société Civile de Placement Immobilier) — a diversified European real-estate investment fund with opportunistic strategy, ISR label, 12% HT annual management fee on rental income, 3% HT acquisition commission, and 5% HT capital-gain commission where gain exceeds 5% of acquisition value. €5,000 minimum investment, no entry/exit subscription fees. Designed for French and European wealth-building through monthly dividend distributions.
- Iroko Next (SCI) SCI (Société Civile Immobilière) — a fund with two performance drivers combining yield real estate and value-creation real estate; Finansol-certified. Maximum 0.9% management fee for directly held properties and 0.5% for participations managed by third parties; 20% HT capital-gain commission; no entry/exit fees. Targeted annual performance 5.68% (2024: 6.21%).
- Iroko Impact (SCI) SCI dedicated to the social and solidarity economy, investing in entities engaged in solidarity and support for people in precarious situations. SFDR Section 9 classified, Finansol-certified. Maximum 0.9% management fee on directly held properties and cash, 0.5% on third-party-managed participations, no entry/exit fees. Target annual performance 6% (2024); capitalization €1.2M supporting 18 beneficiaries.
- Iroko Atlas (SCPI) SCPI — international opportunistic real estate fund investing exclusively outside France, spanning Western Europe, Eastern Europe and North America. Annual management fee 14.4% HT in the Euro zone and 16.8% HT outside the Euro zone; 4.8% HT acquisition commission; 5% HT capital-gain commission where gain exceeds 5% of acquisition value. €5,000 minimum investment, zero subscription fees. Designed for investors seeking non-French European and broader international real-estate diversification.
Quantifiable outcome
- 74M€ collected in Q1 2024, largest collector among SCPI funds that year
- +4 more outcomes
Companies that use Iroko Pharmaceuticals
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
Iroko Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Iroko Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- SpiricacoreLife insurance company offering Iroko fund products as unit of account options to their policyholders
- GeneralicoreMajor insurance company distributing Iroko investment products through their life insurance offerings
- Prepar-ViecoreLife insurer offering Iroko funds as investment options to their clients
- OradeaViecoreLife insurance company distributing Iroko fund products to their policyholder base
- SelenciacoreInsurance partner distributing Iroko investment solutions
- APICILcoreInsurance group offering Iroko SCPI products to their members and policyholders
- AG2R La MondialecoreMajor French insurance group distributing Iroko investment funds as unit of account options
- GaranceminorInsurance company offering Iroko products to their client base
- UMRminorInsurance partner distributing Iroko investment solutions
- CNPcoreMajor French national insurance company distributing Iroko funds as unit of account investments
- En Tandem ImpactminorPartnership showcasing Iroko Impact's socially committed tenants, part of transparency initiative for investors
Scale indicators11 records
Recent moves7 records
Expansion highlights5 records
Iroko Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Amundi Immobilier: Largest French SCPI manager and part of Amundi/P Crédit Agricole group. Competes across the entire SCPI spectrum though typically at higher minimums and with institutional positioning.
- Primonial REIM: Major French SCPI and real estate asset manager with broad product range and extensive life insurance distribution. Direct competitor in the CGP-distributed SCPI market though with significantly larger AUM and longer track record.
- Sofidy: Independent French asset manager specializing in SCPI, OPCI, and SCP with strong CGP distribution. Comparable ESG-focused funds (Sofidy Prime, Immorente) compete directly for retail real estate allocations.
- La Française Real Estate Managers: Established French SCPI/REIT manager with diversified European real estate exposure and institutional client base. Competes with Iroko Zen/Atlas in pan-European real estate allocation.
- Allianz Immovalor: Insurance-owned SCPI manager (Allianz) offering institutional-backed products through life insurance wrappers. Represents the kind of incumbent insurance channel competition Iroko faces for insurer distribution slots.
- Fiducial Gérance: Established French SCPI manager with diversified retail and institutional real estate offerings. Competes in the same mid-market SCPI segment Iroko targets.
Direct peers
- Perial Asset Management: Independent French SCPI manager with comparable ESG positioning and CGP distribution focus. Closest direct competitor among independent SCPI specialists competing for the same wealth advisor shelf space.
- Corum Asset Management: French SCPI specialist (Corum Origin, Corum XL) known for international opportunistic real estate investing — highly comparable to Iroko Atlas strategy and similar European-outside-France positioning.
Emerging players
- Novaxia Investissement: Independent French real estate asset manager with strong ESG/impact focus and fund-of-funds SCPI products. Comparable target audience (ESG-conscious retail) and similar CGP distribution model.
- Urban Premium (Homunity): Digital-first French real estate investment platform (SCPI en nue-propriété, crowdfunding). Competes for the same digitally-engaged retail investors attracted by Iroko's online subscription model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Iroko Pharmaceuticals social profiles
Digital presenceIroko Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Iroko Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles13 records
Iroko Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Iroko Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Iroko Pharmaceuticals
What does Iroko Pharmaceuticals do?
Iroko manages four European real estate investment funds — Iroko Zen SCPI, Iroko Atlas SCPI, Iroko Next SCI, and Iroko Impact SCI — distributed to investors through wealth-management advisors, French life-insurance wrappers (unit-of-account), and direct online subscription. The funds pursue opportunistic, granular, pan-European strategies with no entry fees and a focus on ESG certifications (ISR label, Finansol, SFDR 8/9).
Is Iroko Pharmaceuticals a public or private company?
Iroko Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Iroko Pharmaceuticals founded?
Iroko Pharmaceuticals was founded in 2020. It employs 51 to 100 people.
Where is Iroko Pharmaceuticals based?
Iroko Pharmaceuticals is headquartered in Philadelphia, United States, in the North America region.
How does Iroko Pharmaceuticals make money?
Four revenue lines are on record. Management Fees are the primary driver. The others are acquisition Commissions, work/Development Commissions and capital Gain Commissions.
Who are Iroko Pharmaceuticals's main competitors?
Broad incumbents on record are Amundi Immobilier, Primonial REIM, Sofidy, La Française Real Estate Managers, Allianz Immovalor and Fiducial Gérance. Direct peers are Perial Asset Management and Corum Asset Management. Emerging players are Novaxia Investissement and Urban Premium (Homunity).
Does Iroko Pharmaceuticals have an API?
No public API is recorded for Iroko Pharmaceuticals.
What industry is Iroko Pharmaceuticals in?
Iroko Pharmaceuticals's product category is Real Estate Investment Management. Its primary akta.pro industry code is FSAAALAB, Sustainable/Thematic Investing (Climate, Clean Tech, Water, Biodiversity), with a secondary code of FSANAJAL, ESG Integration / Responsible Investment Funds (Broad ESG). Its NAICS code is 523940 and its SIC code is 6531.